Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

CAPS Rating: 3 out of 5

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.

Results 1 - 20 of 51 : 1 2 3 Next »

Recs

0
Member Avatar Turtlebale (62.52) Submitted: 2/5/2016 8:54:54 AM : Outperform Start Price: $416.10 REGN Score: -6.63

lots of 2016 catalysts

Recs

0
Member Avatar coleman205 (< 20) Submitted: 1/14/2016 6:17:54 PM : Outperform Start Price: $464.59 REGN Score: -18.35

good value

Recs

0
Member Avatar roymarshall (26.22) Submitted: 1/4/2016 3:07:32 PM : Outperform Start Price: $507.11 REGN Score: -19.01

Start to buy if this goes below 500. IMHO, if you don't buy, Sanofi will definitely buy more.

Recs

0
Member Avatar TMFEBCapital (35.16) Submitted: 12/3/2015 10:35:28 AM : Outperform Start Price: $541.66 REGN Score: -20.01

Potential upside tied to expanding drug pipeline and newly approved cholesterol lowering agent could turn this company into a top tier biotech in the coming five years.

Recs

0
Member Avatar graybell (< 20) Submitted: 9/25/2015 12:58:34 PM : Outperform Start Price: $513.55 REGN Score: -22.06

oversold

Recs

0
Member Avatar TMFInnovator (22.65) Submitted: 9/17/2015 10:24:39 AM : Outperform Start Price: $516.36 REGN Score: -24.21

A really nice 1-2-3 punch with Eylea (macular degeneration), Praluent (cholesterol), and Sarilumab (arthritis)..

Eylea: http://www.fiercepharma.com/story/eylea-expected-keep-delivering-regeneron-praluent-starts-step/2015-07-02

Praluent: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455883.htm

Sarilumab: http://www.prnewswire.com/news-releases/regeneron-and-sanofi-announce-positive-topline-results-from-phase-3-studies-with-sarilumab-in-patients-with-rheumatoid-arthritis-300086919.html

Recs

0
Member Avatar npuva62 (< 20) Submitted: 8/17/2015 10:23:25 PM : Outperform Start Price: $578.95 REGN Score: -23.30

A potentially lucrative pipeline of new treatments coming online here but big pharmacy players like CVS could apply pressure against wide adoption of expensive products.

Recs

0
Member Avatar ruinas (27.45) Submitted: 6/2/2015 7:30:14 PM : Underperform Start Price: $509.64 REGN Score: +13.66

Biotech stocks Are overpriced and should drop in price.

Recs

0
Member Avatar CMFLovePeace (< 20) Submitted: 5/19/2015 9:07:58 PM : Outperform Start Price: $488.01 REGN Score: -10.27

Co-founder is CEO.

Recs

0
Member Avatar WSMOOT19 (70.48) Submitted: 4/18/2015 12:43:34 AM : Outperform Start Price: $139.20 REGN Score: +139.44

Great Growth

Recs

0
Member Avatar BASSALDMF (46.15) Submitted: 2/1/2015 9:27:46 PM : Outperform Start Price: $419.79 REGN Score: -3.01

NOVEL TARGETED MEDICINE IS ON THE RISE...MY PREDICTION IS 516.00 IN 6 MONTHS.

Recs

0
Member Avatar 4b796c65 (< 20) Submitted: 11/29/2014 4:34:26 AM : Outperform Start Price: $413.98 REGN Score: +1.13

Three pipeline products that may be approved within the next few years. Plus Eylea may be approved for use in Japan and the EU. Good things to come!

Recs

0
Member Avatar wmsk (< 20) Submitted: 11/15/2014 7:57:08 AM : Outperform Start Price: $396.03 REGN Score: +4.15

Its blockbuster drug Eylea, currently used by Ophthalmologists, is increasing. Other drugs in the pipeline will only enhance the stock value.

Recs

0
Member Avatar davidm9999 (69.99) Submitted: 10/19/2014 8:52:59 PM : Underperform Start Price: $367.79 REGN Score: -3.85

As I have outlined 10 times or so to zero feedback and onlooker commentary - REGN is at or near its peak - Roth Capital aka chop shop wants this stock to go to $410 - most optimistic technicians call it $380 - currently $370 in other words, it will be facing a literal mountain of negative pressure in order to move any higher and if it does, it still will not move very far. Point being, and I've made the mistake of shorting this stock on the way up, get shot this stock - preferably outright shorting, but puts will work to, assuming they are appropriately spaced out over the next 24 months

Recs

1
Member Avatar Morass (68.40) Submitted: 9/6/2014 9:08:50 PM : Outperform Start Price: $349.43 REGN Score: +15.58

REGN has a pipeline of potential biotech products.

Recs

0
Member Avatar trackjakeambrose (40.46) Submitted: 7/20/2014 10:06:15 PM : Outperform Start Price: $306.20 REGN Score: +29.09

1 ;-)

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 5/7/2014 6:06:24 PM : Underperform Start Price: $310.40 REGN Score: -28.24

Biotech bull market top

Recs

1
Member Avatar TMFTycoon (61.75) Submitted: 3/20/2014 3:53:53 PM : Outperform Start Price: $328.69 REGN Score: +15.90

Things are looking good for Eylea, one of Regeneron's drugs, and it is scheduled for further regulatory decisions and Phase III testing later this year.

Recs

0
Member Avatar Chemdawg (28.49) Submitted: 3/7/2014 2:07:49 AM : Outperform Start Price: $341.83 REGN Score: +12.06

12 shots in the eye per year Vs 52 shots in the eye for the competition ....which would you choose?

Recs

0
Member Avatar d3ming (< 20) Submitted: 1/31/2014 1:30:34 PM : Outperform Start Price: $291.02 REGN Score: +25.62

zzporte

Results 1 - 20 of 51 : 1 2 3 Next »

Featured Broker Partners